Decoy Therapeutics
DCOY
4 hedge funds and large institutions have $111K invested in Decoy Therapeutics in 2022 Q4 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 12 closing their positions.
0% more ownership
Funds ownership: 0% → 0% (+0%)
75% less funds holding
Funds holding: 16 → 4 (-12)
83% less capital invested
Capital invested by funds: $671K → $111K (-$560K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 12
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$60K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$42.6K |
| 3 |
State Street
Boston,
Massachusetts
|
-$28K |
| 4 |
Renaissance Technologies
New York
|
-$24.8K |
| 5 |
Millennium Management
New York
|
-$23K |
DCOY Hedge Fund Activity: Q4 2022 in Review
4 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q4 2022, worth a combined $111K — down 83% from $671K a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of DCOY and 0 opened new positions — a net loss of 12 holders — while 2 trimmed existing stakes and 0 added.
The largest seller was Two Sigma Advisers, exiting entirely with an estimated $60K sold.
- 4 institutional investors held Decoy Therapeutics (DCOY) as of Q4 2022, down from 16 in Q3 2022.
- Funds reported $111K of Decoy Therapeutics stock for Q4 2022, down 83% quarter-over-quarter.
- 0 funds opened new Decoy Therapeutics positions in Q4 2022 and 12 closed out, a net change of -12 holders.
- The largest Decoy Therapeutics seller in Q4 2022 was Two Sigma Advisers, an estimated $60K sold.
Based on aggregated 13F filings for Q4 2022.